Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Du bruger tilsyneladende en bredere skærm. Vil du gerne give denne side en bredere visningsoplevelse?

Ascelia Pharma - What happened during Q1?

Af Claus ThestrupCEO, Sweden
Ascelia Pharma

You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.

Meet and ask questions to Deputy CEO Julie Waras Brogren from Ascelia Pharma on 21 May 2024 at 1:00 PM when she gives investors an update on Q1 2024.

After the closing of Q1, Ascelia Pharma confirmed that SPARKLE image reading has been completed and expects headline results in first half of May 2024. Furthermore, the company announced that they have exercised the 2nd tranche of loan facility with Formue Nord Fokus A/S.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE)

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./ Claus Thestrup 13.24 PM 23-04-2024.

Seneste videoer

UPM and Sappi are planning a joint venture in graphic papers
04.12.2025, 13.00 UPM-Kymmene
GreenMobility: How far away are driverless cars in Denmark
04.12.2025, 11.32 GreenMobility
Systemair, Audiocast, Q2'25/26
04.12.2025, 09.00 Systemair
HCA Morgenbørs 03/12 - Overvejende positive futures og fokus på ISS
03.12.2025, 09.23 Novo Nordisk
Hafnia – Presentation of the quarterly report for Q3 2025
02.12.2025, 11.00 Hafnia
Vis alle videoer
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.